Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy
Issued Date
2026-01-01
Resource Type
ISSN
1756283X
eISSN
17562848
Scopus ID
2-s2.0-105027769073
Journal Title
Therapeutic Advances in Gastroenterology
Volume
19
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Advances in Gastroenterology Vol.19 (2026)
Suggested Citation
Pudipeddi A., Chaemsupaphan T., Arzivian A., Kim Y.S., Paramsothy S., Kariyawasam V., Leong R.W. Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy. Therapeutic Advances in Gastroenterology Vol.19 (2026). doi:10.1177/17562848251414825 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114364
Title
Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy
Corresponding Author(s)
Other Contributor(s)
Abstract
Vedolizumab (VED) is a gut-selective monoclonal antibody and an effective biological agent for many patients with inflammatory bowel disease (IBD). Therapeutic drug monitoring has been used to optimise treatment with other biological agents; however, the clinical applicability of measuring vedolizumab trough concentrations is unclear. Initial registration trial data demonstrated a positive exposure–efficacy relationship of vedolizumab in IBD. However, there is conflicting data in more recent studies, with no definitive benefit of vedolizumab dose-escalation and no consistent target vedolizumab trough concentration identified. Also, unlike with anti-tumour necrosis factor agents, the clinical benefit of immunomodulator co-therapy with vedolizumab is uncertain. Although initial research suggested no clinical advantage of combining vedolizumab with an immunomodulator, more recent studies have shown potential benefit. This narrative review aims to explore current evidence on vedolizumab pharmacokinetics and whether immunomodulator co-therapy should be considered with vedolizumab.